Vanessa Marie Green, NP
Nurse Practitioner · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Stanford Health Care · Texas Oncology PA
Looking this up.
Hospitals listed: Texoma Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Vanessa Marie Green’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Texoma Medical CenterDenison, TXAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Universal Health Services, which runs 158 hospitals in 38 statesPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.429, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
See every measure and the patient survey for Texoma Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.429 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.05 (0.08 to 2.01) · 1,685 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.93 (0.64 to 1.22) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 157.35 (106.72 to 207.99) · 111 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 177 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 287 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.4 · 319 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.2 · 717 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.2 · 999 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.4 · 487 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 4,835 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.32) · 10,380 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.04 to 0.41) · 10,880 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.68 (0.65 to 4.71) · 1,650 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.18 (0.62 to 3.75) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.76 (0.35 to 3.16) · 1,677 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 12.2 (6.29 to 18.12) · 328 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.81 (1.91 to 9.7) · 304 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.93 (0.47 to 3.4) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.79) · 8,913 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 38 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.491 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.601 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.498 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 407 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.6 · 1,183 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -4.7 · 303 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9 · 845 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 34.4 · 1,136 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.8 · 1,567 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.8 · 43 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.6 · 199 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 433 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.5 to 18.9) · 1,039 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 406 cases | No different | Jan 2024 – Dec 2024 |
What patients said (622 patients answered, 17% of those asked)
| Cleanliness | 2 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 4 |
| Recommend hospital | 3 |
| Room was "always" clean | 63% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 79% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 65% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 62% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$20,339
Medicare paid this office $20,339 for 189 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 152 | $13,522 | $81 |
| Long return visit (40+ min) | 22 | $2,574 | $117 |
| Insertion of needle into vein for collection of blood sample | 66 | $822 | $9 |
| Blood test, comprehensive group of blood chemicals | 57 | $693 | $10 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 62 | $616 | $8 |
See all 8 services
| Return visit (30+ min) | 152 | $13,522 | $81 |
| Long return visit (40+ min) | 22 | $2,574 | $117 |
| Insertion of needle into vein for collection of blood sample | 66 | $822 | $9 |
| Blood test, comprehensive group of blood chemicals | 57 | $693 | $10 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 62 | $616 | $8 |
| Ferritin (blood protein) level | 22 | $321 | $13 |
| Iron binding capacity | 21 | $197 | $9 |
| Iron level | 21 | $146 | $6 |
Who their Medicare patients are
189 Original Medicare patients in 2024. Average age 75 · Under 65 7% · 85 and older 12% · Women 58% · Also on Medicaid 7% · Health risk score 1.67. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 75% · Coronary heart disease 39% · COPD 39% · Cancer 38% · Diabetes 37% · Chronic kidney disease 34% · Depression 25% · Heart failure 24% · Atrial fibrillation 23% · Stroke 11% · Dementia 8%.
The office billed $90,969, Medicare allowed $24,855 and paid $20,339; for 571 services of 28 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Drugs they prescribed that Part D paid
$4,697
Pharmacies billed $4,697 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
88 generic and fewer than 11 brand-name prescriptions · $4,697 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lidocaine-Prilocaine | 25 | $318 | $13 |
| Ondansetron Odt | 13 | $172 | $13 |
| Prochlorperazine Maleate | 14 | $128 | $9 |
| Potassium Chloride | 14 | $20 | $1 |
Money from drug and device companies
$1,022 in 2025
| 2025 | 22 | 32 | None | $1,022 |
| 2024 | 5 | 8 | None | $158 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Rybrevant | $222 | 4 payments
|
| Daiichi Sankyo | Enhertu | $179 | 4 payments
|
| Incyte | Jakafi | $109 | 2 payments
|
| Abbvie | Emrelis | $67 | 3 payments
|
| Genzyme | Ayvakit | $37 | 1 payment
|
| Novartis Pharmaceuticals | Kisqali | $34 | 1 payment
|
See all 32 published payments
| Genzyme | Meals · 2025-10-22 | Ayvakit | $37 |
| Abbvie | Meals · 2025-10-16 | Emrelis | $31 |
| Astellas Pharma US | Meals · 2025-09-18 | Vyloy | $26 |
| Aveo Pharmaceuticals | Meals · 2025-09-15 | Fotivda | $19 |
| Geron | Meals · 2025-09-09 | Rytelo | $27 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-28 | Opdivo | $15 |
| Array Biopharma | Meals · 2025-07-22 | Braftovi | $21 |
| Incyte | Education · 2025-07-18 | None | $93 |
| Daiichi Sankyo | Meals · 2025-07-14 | Datroway | $28 |
| Daiichi Sankyo | Meals · 2025-07-14 | Datroway | $1 |
| Novartis Pharmaceuticals | Meals · 2025-07-02 | Kisqali | $34 |
| Abbvie | Meals · 2025-06-25 | Venclexta | $16 |
| Adc Therapeutics America | Meals · 2025-06-25 | Zynlonta | $29 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-06-17 | Nubeqa | $17 |
| Merck Sharp & Dohme | Meals · 2025-06-17 | Keytruda | $24 |
| Janssen Biotech | Meals · 2025-06-16 | Carvykti | $26 |
| Syndax Pharmaceuticals | Meals · 2025-06-12 | None | $25 |
| Incyte | Meals · 2025-06-10 | Jakafi | $16 |
| Janssen Biotech | Meals · 2025-06-09 | Tecvayli | $19 |
| Daiichi Sankyo | Meals · 2025-06-09 | Enhertu | $125 |
| Daiichi Sankyo | Meals · 2025-06-05 | Enhertu | $26 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-19 | Fruzaqla | $28 |
| Genentech USA | Meals · 2025-05-16 | Tecentriq | $14 |
| Janssen Biotech | Education · 2025-05-14 | Erleada | $78 |
| BeOne Medicines USA | Meals · 2025-05-14 | Brukinsa | $27 |
| Pfizer | Meals · 2025-05-06 | Ibrance | $14 |
| Agios Pharmaceuticals | Meals · 2025-05-06 | Pyrukynd | $14 |
| Eisai | Meals · 2025-05-01 | Lenvima | $25 |
| Abbvie | Meals · 2025-04-23 | None | $20 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-05 | Opdivo | $19 |
| SpringWorks Therapeutics | Meals · 2025-01-16 | Ogsiveo | $29 |
| Janssen Biotech | Education · 2025-01-07 | Rybrevant | $99 |
See earlier years (2024)
2024: $158
| Novartis Pharmaceuticals | Pluvicto | $39 | 2 payments
|
| Karyopharm Therapeutics | Xpovio | $34 | 2 payments
|
| Incyte | Monjuvi | $33 | 2 payments
|
| Inari Medical | Flowtriever Catheter, S | $33 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $19 | 1 payment
|
Professional record
- NPI
- 1023850930
- Group
- Stanford Health Care · Texas Oncology PA
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X); Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2024-06-11
- NPI last updated
- 2026-08-21
- NPI record certified
- 2026-08-21
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 3500 Victory Group Way Ste 300, Frisco, TX, 75034